PODD Stock Recent News

The Omnipod maker reported 113% earnings growth, sending shares higher.

The Investment Committee give you their top stocks to watch for the second half.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the upcoming investor conferences (all Eastern Time): Wells Fargo 2025 Healthcare Conference in Boston on September 4 at 3:00 p.m. Baird 2025 Global Healthcare Conference in New York City on September 9 at 12:15 p.m. Bernstein Insights: Healthcare Leaders & Disruptors Forum in New York Ci.

PODD delivered strong Q2 results, exceeding revenue guidance, improving gross margin, and launching the Omnipod 5 iPhone app, strengthening its ecosystem position. Omnipod 5's pharmacy channel penetration and positive clinical data support sustained >20% annual revenue growth and margin expansion over the next 3-5 years. The market underestimates the long-term impact of pharmacy distribution, which reduces onboarding friction, broadens payer access, and improves retention economics.

PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Insulet Corporation  PODD reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents.

Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjamin - Executive VP, Chief Product & Customer Experience Officer June Lazaroff - Senior Director of Investor Relations Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Issie Kirby - Redburn (Europe) Limited, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Jeffrey D.

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Insulet (PODD 9.87%), a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong outperformance: GAAP revenue rose to $649.1 million, beating estimates by nearly $35 million, while Adjusted earnings per share (EPS) (non-GAAP) topped analyst forecasts by $0.25.